US Patent

US8206737 — Hypotensive lipid-containing biodegradable intraocular implants and related methods

Method of Use · Assigned to Allergan Inc · Expires 2027-04-07 · 1y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects biocompatible intraocular implants that release a prostamide component to treat or reduce symptoms of an ocular condition.

USPTO Abstract

Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce at least one symptom of an ocular condition, such as glaucoma.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2759 — Lumigan

Patent Metadata

Patent number
US8206737
Jurisdiction
US
Classification
Method of Use
Expires
2027-04-07
Drug substance claim
No
Drug product claim
No
Assignee
Allergan Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.